



New Targeted Therapies in Cancer-2024

Guest Editor:

Dr. Rosaria Chilà

IFOM ETS - The AIRC Institute of
Molecular Oncology, 20139 Milan,
Italy

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editor

Different molecular targets have been explored, such as growth factors, cell surface molecules and receptors, but also non-coding RNAs and entire signaling pathways. Molecules targeting BCR-ABL, BRAF, MEK, EGFR, ALK are few examples of targeted therapies that showed important results in cancer patients. However, depending the effectiveness on the presence of the altered target, the number of patients taking advantage from these treatments is limited. In addition, low response and resistance to targeted drugs have been documented, together with unexpected side effects. Just few molecules among hundreds of potential drug candidates reach the market, therefore further investigation is warranted.

Nowadays, the huge progresses of technological tools allow a deep investigation of tumor heterogeneity and clonality, essential in determining the success of targeted therapies. This Special Issue is aimed to highlight recent discoveries in the field of New Targeted Therapies in Cancer, concerning different kind of molecules, alternative therapeutic strategies and novel targets.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Biochemistry & Molecular Biology*) / CiteScore - Q1 (*Inorganic Chemistry*)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI